Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
BMJ Open Ophthalmol ; 8(Suppl 3): A1, 2023 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-37797997

RESUMO

INTRODUCTION: Prompt detection of childhood uveitis is key to minimising negative impact. From an internationally unique inception cohort, we report pathways to disease detection.UNICORNS is a national childhood non-infectious uveitis study with longitudinal collection of a standardised clinical dataset and patient reported outcomes. Descriptive analysis of baseline characteristics are reported.Amongst 150 recruited children (51% female, 31% non-white ethnicity) age at detection ranged from 2-18yrs (median 10). In 69%, uveitis was diagnosed following onset of symptoms: time from first symptoms to uveitis detection ranged from 0-739days (median 7days), with longer time to detection for those presenting initially to their general practitioner. Non symptomatic children were detected through JIA/other disease surveillance (16%), routine optometry review (5%) or child visual health screening (1%). Commonest underlying diagnoses at uveitis detection were JIA (17%), TINU (9%, higher than pre-pandemic reported UK disease frequency) and sarcoid (1%). 60% had no known systemic disease at uveitis detection. At disease detection, in at least one eye: 34% had structural complications (associated with greater time to detection - 17 days versus 4 days for uncomplicated presentation).The larger relative proportions of children with non-JIA uveitis reported here increase the importance of improving awareness of childhood uveitis amongst the wider clinical communities. There is scope for improvement of pathways to detection. Forthcoming analysis on the full cohort (251 recruited to date across 33 hospitals and 4 nations) will provide nationally representative data on management and the determinants of visual and broader developmental/well-being outcomes.


Assuntos
Artrite Juvenil , Uveíte , Criança , Humanos , Feminino , Pré-Escolar , Adolescente , Masculino , Estudos de Coortes , Artrite Juvenil/complicações , Uveíte/diagnóstico , Reino Unido/epidemiologia
2.
Pediatr Neurol ; 23(2): 167-8, 2000 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-11020644

RESUMO

Six patients with medically refractory epilepsy secondary to hypothalamic hamartomas were treated with intermittent stimulation of the left vagal nerve. Three of the patients had remarkable improvements in seizure control. Four of these six patients had severe autistic behaviors. Striking improvements in these behaviors were observed in all four during treatment with intermittent stimulation. This finding suggests that vagal nerve stimulation can control seizures and autistic behaviors in patients with hypothalamic hamartomas.


Assuntos
Terapia por Estimulação Elétrica , Epilepsia/terapia , Hamartoma/complicações , Doenças Hipotalâmicas/complicações , Nervo Vago , Adolescente , Transtorno Autístico/psicologia , Transtorno Autístico/terapia , Criança , Epilepsia/etiologia , Epilepsia/psicologia , Feminino , Hamartoma/psicologia , Humanos , Doenças Hipotalâmicas/psicologia , Masculino
4.
Growth Horm IGF Res ; 23(3): 81-7, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-23433655

RESUMO

OBJECTIVE: Since limited data exist on adults with Prader-Willi syndrome (PWS) and growth hormone (GH) treatment, we report our experience on the effects of treatment for one year on body composition, physical activity, strength and energy expenditure, diet, general chemistry and endocrine data with quality of life measures. DESIGN: We studied 11 adults with PWS (6F:5M; average age=32 yrs) over a 2 year period with GH treatment during the first year only. Electrolytes, IGF-I, glucose, thyroid, insulin, lipids, body composition, physical activity and strength, diet, energy expenditure and quality of life data were collected and analyzed statistically using linear modeling at baseline, at 12 months following GH therapy and at 24 months after treatment cessation for 12 months. RESULTS: Total lean muscle mass was significantly increased (p<0.05) during GH treatment along with moderate-vigorous physical activity and plasma IGF-I and HDL levels, but returned to near baseline after treatment. Percent body fat decreased during the 12 months of GH treatment but increased after treatment. CONCLUSIONS: Previously reported beneficial effects of GH treatment in children with PWS were found in our adults regarding body composition, physical activity and plasma HDL and IGF-I levels. Several beneficial effects diminished to near baseline after cessation of GH treatment for 12 months supporting the continuation of treatment in PWS into adulthood and possibly adults not previously treated during childhood.


Assuntos
Hormônio do Crescimento Humano/administração & dosagem , Fator de Crescimento Insulin-Like I/metabolismo , Síndrome de Prader-Willi/tratamento farmacológico , Qualidade de Vida , Tecido Adiposo , Adolescente , Adulto , Composição Corporal , Metabolismo Energético , Exercício Físico , Jejum , Humanos , Lipídeos/análise , Masculino , Pessoa de Meia-Idade , Síndrome de Prader-Willi/sangue , Prognóstico , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA